Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hasten Raises $315 Million from CBC and Abu Dhabi's Sovereign Fund for In-Licensings

publication date: Apr 20, 2023

Hefei’s Hasten Biopharma raised $315 million in new cash from a group led by CBC Group, a Singapore life science investor, and Abu Dhabi’s Mubadala Investment Company. One year ago, Hasten's acquired China rights for five cardiovascular and metabolism drugs from Japan’s Takeda in a $322 million deal. To speed up its growth, the company is developing a pipeline of innovative late-stage products, using its existing commercial platform. Hasten describes itself as an innovation-driven biopharma backed by CBC, Hefei Industry Investment Group and Feidong County of Hefei City. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital